Flutiform (Vectura/Mundipharma/Kyorin) Drug Overview 2017/18-2026 - A Pressurized Metered-Dose Inhaler Formulation Which Contains a Combination of Fluticasone Propionate and Formoterol - ResearchAndMarkets.com

DUBLIN--()--The "Drug Overview: Flutiform" report has been added to ResearchAndMarkets.com's offering.

Flutiform ([fluticasone propionate + formoterol fumarate]; Vectura/Mundipharma/Kyorin) is a pressurized metered-dose inhaler formulation which contains a combination of fluticasone propionate and formoterol. Fluticasone propionate is an inhaled corticosteroid which has potent anti-inflammatory activity when delivered by inhalation, while formoterol fumarate is a long-acting beta 2 agonist which acts as a bronchodilator.

Key Topics Covered

  1. Product Profiles
  2. Flutiform: Asthma

List of Figures

Figure 1: Asthma - Current and future market dynamics analysis

Figure 2: Drug assessment summary of Flutiform in asthma

Figure 3: Drug assessment summary of Flutiform in asthma

List of Tables

Table 1: Flutiform drug profile

Table 2: Flutiform pivotal trial data in asthma

Table 3: Flutiform Phase III trials in asthma

Table 4: Flutiform sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/xtkwtp/flutiform?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs